How does the location of the tumor (intrahepatic vs. perihilar vs. distal) affect prognosis and surgical planning?

Intrahepatic tumors often require liver resection or transplant; perihilar (Klatskin) tumors may need complex bile‑duct reconstruction and sometimes extended hepatectomy; distal tumors are usually treated with pancreaticoduodenectomy (Whipple). Survival is generally longest for resected intrahepatic disease, intermediate for perihilar, and shortest for distal tumors when surgery is not possible.

If I have risk factors like primary sclerosing cholangitis, how often should I be screened for cholangiocarcinoma?

Patients with PSC are usually screened every 6–12 months with magnetic resonance cholangiopancreatography (MRCP) and serum CA 19‑9; earlier or more frequent imaging may be advised if symptoms develop.

What early signs should prompt a doctor to investigate possible cholangiocarcinoma?

lthough early disease often has no symptoms, new onset jaundice, persistent itching, dark urine, pale stools, or unexplained weight loss should trigger liver function tests and imaging to rule out bile‑duct obstruction.

What are the main treatment options for a tumor that is confined to the bile ducts but not resectable?

For unresectable but localized disease, a combination of chemotherapy (e.g., gemcitabine‑cisplatin) and radiation (often called chemoradiation) can shrink the tumor, and some centers offer liver transplantation after strict selection criteria.

Cholangiocarcinoma

Cholangiocarcinoma is a group of cancers originating in the bile ducts that is typically diagnosed in advanced stages due to its lack of early symptoms.

Overview & Types

Cholangiocarcinoma is a group of cancers that begin in the bile ducts. Bile ducts are branched tubes that connect the liver and gallbladder to the small intestine. They carry bile, a fluid that helps the body digest fats in food. Bile is made in the liver and stored in the gallbladder before being released into the small intestine after eating.

Cholangiocarcinoma is classified by its location in relation to the liver:

Intrahepatic cholangiocarcinoma: Begins in the small bile ducts within the liver. This is the least common form, accounting for less than 10 percent of all cases.
Perihilar cholangiocarcinoma (also known as a Klatskin tumor): Begins in the hilum, where the right and left major bile ducts join and leave the liver. This is the most common form, accounting for more than half of all cases.
Distal cholangiocarcinoma: Begins in the bile ducts outside the liver.

The perihilar and distal forms, which both occur outside the liver, are sometimes grouped together and called extrahepatic cholangiocarcinoma.

Symptoms

The three types of cholangiocarcinoma do not usually cause any symptoms in their early stages. Consequently, this cancer is usually not diagnosed until it has already spread beyond the bile ducts to other tissues. Symptoms often result when bile ducts become blocked by the tumor. The most common symptom is jaundice, in which the skin and whites of the eyes turn yellow.

Other nonspecific symptoms can include:

Extreme tiredness (fatigue)
Itching
Dark-colored urine
Loss of appetite
Unintentional weight loss
Abdominal pain
Light-colored and greasy stools

Most people who develop cholangiocarcinoma are older than 65. Affected individuals can survive for several months to several years after diagnosis, depending on the location of the cancer and how advanced it is.

Frequency

Cholangiocarcinoma affects 8,000 people each year in the United States. This type of cancer occurs much more frequently in Southeast Asian countries such as Thailand, where it is related to infection with a common parasite. For unknown reasons, cholangiocarcinoma occurs slightly more often in men than in women.

Causes & Risk Factors

Cancers occur when a buildup of genetic mutations allows cells to grow and divide uncontrollably to form a tumor. In most cases of cholangiocarcinoma, these genetic changes are acquired during a person's lifetime and are present only in the bile duct cells that give rise to the tumor. These changes are called somatic mutations and are not inherited.

Somatic mutations associated with cholangiocarcinoma can occur in:

Tumor suppressors: Genes that keep the growth and division of cells tightly regulated. Mutations in or deletions of these genes allow uncontrolled cell division.
Oncogenes: Genes that, when abnormally activated, have the potential to cause normal cells to become cancerous.

Researchers have also investigated inherited variations (germline mutations) present in essentially all of the body's cells, but no specific inherited changes have been found to be major risk factors for this disease.

Several non-genetic risk factors for cholangiocarcinoma have been identified, including:

Primary sclerosing cholangitis (a bile duct disease)
Bile duct stones or cysts
Exposure to certain chemical toxins used in manufacturing
Infection with parasitic worms that live in the human bile ducts (primarily in Southeast Asia)
Long-term infection with viral hepatitis B or hepatitis C
Scarring of the liver (cirrhosis)
Chronic diseases such as inflammatory bowel disease and diabetes
Lifestyle factors, including smoking, alcohol use, and obesity

While studies suggest a combination of genetic, environmental, and lifestyle factors influence risk, most people who develop cholangiocarcinoma do not have any of the identified risk factors.

Inheritance

Cholangiocarcinoma is not inherited. Studies suggest that blood relatives of an affected person may have an increased risk of developing this cancer compared with the general population, but most people with cholangiocarcinoma do not have a family history of the disease.

Other Names for This Condition

CC
Cholangiocarcinoma of biliary tract
Cholangiocellular carcinoma
Distal cholangiocarcinoma
Extrahepatic cholangiocarcinoma
Intrahepatic cholangiocarcinoma
Perihilar cholangiocarcinoma